Evidence map›Paper›PMID 41614390›Full record

ArticleAnnals of medicine2026

Kinetics and prognostic value of heparin binding protein at the ST-segment-elevation myocardial infarction.

Yueying Wang, Tianqi Zhu, Wenli Zhang, Ruiyan Zhang, Hongyang Xie, Xuezheng Qu, Keremu Buayiximu, Zhengbin Zhu, Jingwei Ni, Run Du and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yueying WangDepartment of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Tianqi ZhuDepartment of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Wenli ZhangDepartment of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ruiyan ZhangDepartment of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Hongyang XieDepartment of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xuezheng QuDepartment of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Keremu BuayiximuDepartment of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhengbin ZhuDepartment of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jingwei NiDepartment of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Run DuDepartment of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jinzhou ZhuDepartment of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiaoqun WangDepartment of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Fenghua DingDepartment of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiaoxiang YanDepartment of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ping LiDepartment of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhihong XuDepartment of Geriatrics, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Weiwei QuanDepartment of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis research aimed to explore the potential role of heparin-binding protein (HBP) as a prognostic biomarker for adverse events among individuals diagnosed with ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (pPCI).

methodsThis cohort study enrolled 215 consecutive patients with STEMI following pPCI. Plasma HBP and high-sensitivity cardiac troponin I (hs-cTnI) levels were measured at admission, and at 24h, 48h, and 72h after pPCI. During a median follow-up period of 1.5 years, major adverse cardiovascular events (MACE) were recorded.

resultsPlasma HBP levels decreased from a median of 58.04 (IQR 30.38, 106.04) ng/mL at admission to 23.80 (IQR 14.03, 44.51) ng/mL at 72 h (HBP

conclusionsElevated HBP levels following STEMI were associated with an increased risk of adverse outcomes and may serve as a novel and valuable prognostic marker in patients with STEMI.

Indexed as

Blood ProteinsCarrier ProteinsPercutaneous Coronary InterventionST Elevation Myocardial InfarctionAgedAntimicrobial Cationic PeptidesBiomarkersFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisTroponin IAntimicrobial Cationic PeptidesAZU1 protein, humanBiomarkersBlood ProteinsCarrier ProteinsTroponin Iacute ST-segment elevation myocardial infarctionheart failureHeparin binding proteinmajor adverse cardiac events

Identifiers

PMID41614390
PMCPMC12862846

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.